2020
Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism
Blackburn JK, Curry DW, Thomsen AN, Roth RH, Elsworth JD. Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism. Experimental Neurology 2020, 327: 113234. PMID: 32044330, PMCID: PMC7089823, DOI: 10.1016/j.expneurol.2020.113234.Peer-Reviewed Original ResearchConceptsParaoxonase 2Novel neuroprotective mechanismParaoxonase-2 expressionAnti-diabetic drug pioglitazoneReactive oxygen species productionNeuroprotective strategiesNeuroprotective mechanismsBrain traumaMouse striatumOxygen species productionParkinson's diseaseAlzheimer's diseaseTherapeutic potentialPioglitazoneDiseaseOxidative stressDrug pioglitazoneSpecies productionBrainNeuroprotectionIschemiaStriatumExpressionPathologyTrauma
1989
Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions
Elsworth J, Deutch A, Redmond D, Taylor J, Sladek J, Roth R. Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions. Neuroscience 1989, 33: 323-331. PMID: 2622529, DOI: 10.1016/0306-4522(89)90212-1.Peer-Reviewed Original ResearchConceptsHomovanillic acid concentrationsParkinson's diseaseStriatal regionsHomovanillic acid/dopamine ratioGross motor abnormalitiesDepletion of dopamineHomovanillic acid levelsLoss of dopamineIdiopathic Parkinson's diseaseCaudate nucleus dopamineAsymptomatic monkeysTetrahydropyridine (MPTP) treatmentAsymptomatic groupSymptomatic groupDopamine lossTetrahydropyridine (MPTP) toxicityMotor abnormalitiesDopamine ratioCaudate nucleusSignificant negative correlationVentromedial regionStriatum
1987
Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum
Elsworth J, Deutch A, Redmond D, Sladek J, Roth R. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Life Sciences 1987, 40: 193-202. PMID: 3491946, DOI: 10.1016/0024-3205(87)90359-6.Peer-Reviewed Original ResearchConceptsSubstantia nigraParkinsonian disabilityDA neuronsSymptomatic animalsMedial regionAsymptomatic animalsHVA/DA ratioLateral regionsDA concentrationPrimate substantia nigraDA histofluorescenceNigrostriatal pathwayTetrahydropyridine (MPTP) toxicityDopaminergic neuronsContralateral halfDA ratioDopaminergic cellsLipofuscin fluorescenceCell bodiesStriatumIndividual neuronsNeuronsDifferential responsivenessMarked lossDopamine
1986
Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Deutch A, Elsworth J, Goldstein M, Fuxe K, Redmond D, Sladek J, Roth R. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience Letters 1986, 68: 51-56. PMID: 3487756, DOI: 10.1016/0304-3940(86)90228-4.Peer-Reviewed Original ResearchConceptsA8 regionDA neuronsSubstantia nigraDopamine cell groupsDopaminergic neuronsDopamine neuronsImmunohistochemical examinationPreferential vulnerabilityHomovanillic acidBiochemical assessmentCell groupsMarked depletionNeuronsSame animalsSignificant decreaseMarked lossMPTPStriatumNigraVervet monkeysMidbrainTetrahydropyridine
1980
Dopamine Oxidation and Its Inhibition by (—)-Deprenyl in Man
Glover V, Elsworth J, Sandler M. Dopamine Oxidation and Its Inhibition by (—)-Deprenyl in Man. Journal Of Neural Transmission. Supplementa 1980, 163-172. PMID: 6776235, DOI: 10.1007/978-3-7091-8582-7_18.Peer-Reviewed Original Research